Trial Profile
A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) PET status and cognitive decline.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 22 Jul 2015 According to an Eli Lily media release, data from this study were presented today at the Alzheimer's Association International Conference 2015 (AAIC).
- 22 Jul 2015 Results published in an Eli Lily media release.
- 30 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov